Patent Application
20210324429
The content of the electronically submitted sequence listing (Name: 7526-79_SEQ_LISTING.txt; Size: 9.83 kilobytes; and Date of Creation: Feb. 1, 2021) filed with the application is incorporated herein by reference in its entirety.
The present invention relates to a process for the production by direct fermentation of poly L-lactic acid (PLLA) from a carbon source by engineered prokaryotic or eukaryotic cells or of poly D-lactic acid (PDLA) from sugars by engineered eukaryotic cells. The invention also refers to cells having a metabolic flow redirected for the synthesis of enantiomerically pure polymers such as PDLA or PLLA starting from a carbon source, which preferably derives from residual biomasses of production chains.
Polylactic acid (PLA) is a biodegradable biopolymer derived from lactic acid. Due to its chemical-physical properties, it is an unbranched aliphatic polyester, belonging to the class of thermoplastic polymers. Because of its characteristics, PLA is very similar to polyethylene terephthalate (PET), a common plastic used mainly for food packaging. PET has a petrochemical derivation, while PLA is obtained from the polymerization of lactic acid, obtained in turn by fermentation (Jamshidian et al., 2010; Tsuji et al., 2011). The need to avoid processes based on the use of oil, a fossil resource that is depleting due to rapid human consumption, in favor of bio-based systems, is driving several companies to use bioplastics.
There are several applications of PLA in many sectors, such as: the food sector (packaging, plates, cutlery, glasses, bottles, among others), 3D printing, where it can replace acrylonitrile butadiene styrene (ABS), and the medical field (e.g. biocompatible suture threads, capsules for drug delivery, among others) (Garlotta, 2001; Rasal et al., 2010; Xiao et al., 2012). The versatility of the PLA allows the printing of finished products both in extrusion and in injection, and, remarkably, it is possible to use the machineries and infrastructures already developed for PET (Jamshidian et al., 2010).
PLA can be stained by masterbatch and mixed with other plastics (biodegradable or not, of petrochemical derivation or not), in order to obtain compounds with new properties. In addition, it is possible to find the PLA in co-polymer form, in which lactic acid monomers alternate with other hydroxy acids such as 3-hydroxybutyrate (3HB) or glycolate (Choi et al., 2016; Xiao et al., 2012; Tsuji et al., 2010).
PLA, differently from traditional plastics like PET, is biodegradable in the environment and biocompostable, namely disposable among organic waste. Therefore, a PLA object-product, once its life cycle has ended, is reabsorbed by the soil, favoring the formation of new biomass that can be further used for the production of PLA (Tsuji et al., 2011; Chen and Patel, 2012). As a consequence, the PLA has a circular supply chain thanks to both its origin from renewable biomasses and its intrinsic biodegradability.
The global PLA market (about 210 thousand tons/year in 2017) is growing steadily and production is expected to increase by 50% by 2022 compared to that recorded in 2017 (www.european-bioplastics.org/market/). There are three types of PLA depending on the enantiomeric forms of the constituent monomers: PLLA composed of only L-lactic acid monomers, the PDLA consisting of only D-lactic acid monomers, and PDLLA consisting of a mixture of both monomers (Jamshidian et al., 2010; Tsuji et al., 2011). PDLA and PLLA are in a semi-crystalline form, while PDLLA in amorphous form (Tsuji et al., 2011). The chirality of the monomers constituting the PLA is transferred to the polymer itself (hence PDLA or PLLA), which acquires precise chirality. This leads, in the solid form, in a different interaction between adjacent first chains and in a possible lamellar or crystalline structure peculiar to the two single enantiomers, which can preserve, at least partially, chirality. In particular, even in the form of a thin film, PDLA or PLLA can present morphology and at least partial chirality of surfaces, peculiar to the specific enantiomer (Maillard and Prud′homme, 2010), showing phenomena of circular dichroism.
However, considering the chemical-physical characteristics, these polymers are very similar to each other, for example they are soluble in the same organic solvents (e.g. benzene, chloroform, acetonitrile, etc.). Furthermore, there are no significant differences in terms of melting temperature (Tm˜180° C.), decomposition temperature (˜200° C.), and elongation (20-30%) (Xiao et al., 2012), which mainly depend on the molecular weight of the polymer. From a commercial point of view, the market is dominated by PLLA, which is mainly used for the production of disposable objects. The PDLA has instead a more niche market and applications in the medical field, since, for instance, it may have two beneficial effects for wound healing: (i) providing a protective barrier as a hydrogel; and (ii) serving as an analgesic by sequestering lactate (Goldberg, 2014).
Traditionally, PLA (in its enantiomerically pure and non-pure forms) is produced by a chemical synthesis, starting from the lactic acid obtained by fermentation. Unlike other bioplastics, such as polyhydroxyalkanoates (PHA), no known natural organisms are able to directly synthetize PLA (Chen and Patel, 2012). The industrial production of PLA occurs mainly through a ring-opening polymerization, by means of a cyclic intermediate, called lactide, capable of facilitating the reaction. However, this chemical process has aspects that reduce the environmental sustainability of this bioplastic: (i) to complete the polymerization it is necessary to use stannic octanoate as a catalyst and (ii) to allow chemical polymerization it is necessary that lactic acid is in its protonated form, and not in the form of lactate (Garlotta, 2001; Jamshidian et al., 2010; Rasal et al., 2010; Tsuji et al., 2011). However, since the main supply chains of PLA involve the use of lactic acid bacteria, it becomes necessary to treat the final fermentation product with high amounts of acid. In fact, to allow the growth of these organisms it is necessary to maintain constant the pH of the culture broth around a value of 5 (Okano et al., 2010). Since the pKa of lactic acid is 3.86, under these conditions, the final product is lactate. Consequently, acidification at the end of the fermentation is necessary, as previously mentioned. Moreover, the nutritional needs of lactobacilli are in most cases complex: this determines the need for rich media formulations which are rarely compatible with the use of residual biomasses as a growth substrate. Even more important, this often determines a greater complexity in downstream purification of the desired monomer (Okano et al., 2010). Finally, the lactobacilli, unlike yeasts, are subject to attack by bacteriophages during the fermentation process (Marcó et al., 2012). The use of yeasts is a valid alternative, since many species belonging to this group, for instance the baker's yeast Saccharomyces cerevisiae, are able to grow in soils characterized by low pH values, even lower than a value of 3. Yeasts are unicellular microorganisms widely used by the bioindustry. In particular, S. cerevisiae is the eukaryotic microorganism best known at the molecular, genetic and biochemical level and has the status of GRAS (Generally Recognized As Safe) microorganism (Porro et al., 2011; Li and Borodina, 2015). Furthermore, compared to bacteria such as lactobacilli, yeasts have less complex nutritional requirements that allow their growth on residual biomasses as reported, as a simple sake of example, by Soares et al., (2017), Jansen et al., (2017) and Choi et al., (2002).
Although lactic acid fermentation already represents a sustainable step forward for the production of bioplastics compared to the oil-based production, aiming to further reduce the impact of the conventional process based on chemical polymerization, the direct microbiological synthesis represents an ideal solution. As previously mentioned, in nature no known organisms are able to accumulate polylactic acid. Instead, unlike eukaryotes, many prokaryotes are however able to produce aliphatic polyesters as reserve polymers. Therefore, the development and use of eukaryotic cells for the production of polylactic acid require a deep and new engineering.
The present invention relates to a method for the complete—one-step-biological synthesis of PDLA and/or PLLA, and eukaryotic cells engineered for this purpose. Both biosyntheses include the bioconversion of a carbon source in PDLA and/or PLLA. The metabolic pathways of this invention include the bioconversion of pyruvate to lactate, followed by its activation with a CoA donor, preferably acetyl-CoA, to lactyl-CoA and subsequent polymerization to PDLA and/or PLLA.
Examples of eukaryotic cells capable of producing PDLA have been already described by Dusseaux et al. (WO2017/108577). However, this approach is quite complex. Indeed, this approach requires the addition of lactic acid to the medium for the production of PDLA and the development of a two phase process. Therefore, lactic acid must be produced by a different cell factory and/or by chemical synthesis. In this respect, lactic acid should be considered as a mandatory substrate and not like an intermediate product (which is the case for the invention here disclosed, see below). Being a substrate, the ability to consume lactic acid as carbon source need to be attenuated or eliminated. Furthermore, this approach also requires methods to increase the productivity of intracellular Coenzyme A (CoA) donor. This goal can be obtained by facilitating the accumulation of intracellular CoA donor and/or by disrupting the pathway(s) using CoA.
Surprisingly, despite the wider industrial application of PLLA and the many research skills related to the production of PDLA, no examples of prokaryotic or eukaryotic cells capable of producing PLLA have never been described.
In order to verify the insertion of a metabolic pathway that allows the conversion of carbon source, preferably glucose, into PDLA and/or PLLA, different experiments were performed using engineered yeast strains showing the production of these polymers (see Examples 8-10).
In literature there are examples of genetic modifications of the bacterium Escherichia coli, in order to directly produce pure PDLA or in the form of co-polymer with 3-HB or other monomers (Cho et al., WO2006/126796; Jung et al., 2010; Yang et al., 2010; Choi et al., 2016). However, the use of E. coli has two main limitations: (i) during the fermentation process, the aforementioned microorganism may be subject to attack by bacteriophages, unlike eukaryotic cells (Marcó et al., 2012) and (ii) the metabolism of E. coli is characterized by a mixed acid fermentation in which lactic acid is not the sole fermentation product, with consequent effects on the production yield of the metabolite of interest (Castaño-Cerezo et al., 2009). Remarkably, these examples refer to the incorporation of lactic acid only in the enantiomeric form D, while there are no examples of direct PLLA synthesis, or incorporation of L-lactic acid monomers within the biopolymers produced. This is related to the fact that the system based on E. coli exploits the natural ability of the bacterium to produce only lactic acid in the enantiomeric form D. Conversely, the cell factories developed by the current invention can produce D-lactic and/or L-acid lactic, allowing the synthesis of PDLA and/or PLLA in both eukaryotic and prokaryotic cells.
The subject of the present invention is therefore a method of producing PLLA or PDLA in a cell characterized by a carbon flux directed towards the synthesis of PDLA and/or PLLA.
PDLA synthesis includes the following steps:
PLLA synthesis includes the following steps:
The cells express genes encoding for enzymes aimed at directing the carbon flux towards the synthesis of PDLA and/or PLLA.
In a preferred embodiment, the aforementioned cell is a eukaryotic cell, preferably a yeast cell, more preferably a Saccharomyces cell and even more preferably a Saccharomyces cerevisiae cell.
The yeasts are by way of example described in “The Yeasts” by N. J. W. Kreger-van Rij, 1987. In particular, the genus of yeast can be Saccharomyces, Zygosaccharomyces, Candida, Hansenula, Kluyveromyces, Debaromyces, Nadsonia, Lipomyces, Torulopsis, Kloeckera, Pichia, Schizosaccharomyces, Trigonopsis, Brettanomyces, Cryptococcus, Trichosporon, Aureobasidium, Lipomyces, Phaffia, Rhodotorula, Yarrowia, or Schwanniomyces, among others. Preferably, the yeast is selected from the genus Saccharomyces, and preferably is Saccharomyces cerevisiae. Preferably, the strains of S. cerevisiae are BY4742 (EuroScarf Accession No. Y10000), CEN.PK 102-5B (MATa, ura3-52, his3-11, leu2-3/112, TRP1, MAL2-8c, SUC2) and 113-11C (MATa, ura3-52, his3-11, TRP1, MAL2-8c, SUC2—Dr. P. Kötter, Institute of Microbiology, Johann Wolfgang Goethe-University, Frankfurt, Germany) or further from industrial strains such as AP, BL, SAU (Arome Plus, Blanche, Sauvignone available from AEB group, Italy) e VIN13 (available from Anchor, France). Yeast strains can be haploid or diploid.
The coordinated and appropriately regulated expression of the genes coding for the enzymes involved in the new metabolic pathway, introduced by the inventors of the present invention, can be achieved by using a strong and constitutive endogenous promoter, or by introducing more copies of the exogenous genes, or by means of the conversion of the nucleotide sequence with an optimized nucleotide variant in the codons. These are anyhow routine techniques under the competences of the experts in the field.
In one embodiment of the invention, the eukaryotic cell is able to produce PDLA by expressing exogenous genes, introduced therein, encoding the enzymes involved in polymer synthesis. In a preferred embodiment, the enzymes involved in the aforementioned PDLA production are: i) the enzyme D-lactate dehydrogenase (EC 1.1.1.28), ii) the enzyme propionyl-CoA transferase (EC 2.8.3.1), iii) the enzyme polyhydroxyalkanoate synthase (EC 2.3.1.B3). Any D-lactate dehydrogenase enzyme, propionyl-CoA transferase enzyme and polyhydroxyalkanoate synthase enzyme, whether encoded by an endogenous or heterologous gene, can be used according to the method of this invention. In a preferred embodiment, the heterologous gene encoding the enzyme D-lactate dehydrogenase is a mutated form of E. coli ldhA (Gene ID: 946315 NC_000913.3). Specifically, this sequence has the following nucleotide mutations: T387C, A537G, T636C, A663T, A726G, G777A, A798G, G825A, C828T, C885T (SEQ ID NO: 1).
In another preferred embodiment, the enzyme propionyl-CoA transferase is the mutated version of the enzyme propionyl-CoA transferase (Pct) of Clostridium propionicum. This mutated version, called Pct540, has an amino acid substitution at position 193 in which the valine is replaced by an alanine (V193A) (Park et al., WO2009/022797; Yang et al., 2010). Preferably, the “codon usage” of the heterologous gene encoding the Pct of Clostridium propionicum (Gene ID: AJ276553), mutated in the Pct540 version, is optimized for translation in yeast (SEQ ID NO: 2).
In a further preferred embodiment, the enzyme polyhydroxyalkanoate synthase is the mutated version of the enzyme polyhydroxyalkanoate synthase C1 (PhaC1) of Pseudomonas resinovorans. This mutated version, called PhaC1437Pre, has four amino acid substitutions, in which the glutamic acid at position 130 is replaced by aspartic acid (E130D), the serine at position 325 is replaced by threonine (S325T), the serine at position 477 is replaced from glycine (S477G), glutamine at position 481 is replaced by lysine (Q481K) (Yang et al., 2011). Preferably, the “codon usage” of the heterologous gene encoding the PhaC1 of Pseudomonas resinovorans (Gene Accession no.: AF129396), mutated in the PhaC1437Pre version, is optimized for translation in yeast (SEQ ID NO: 3).
In another embodiment of the invention, the cell is capable of producing PLLA by expressing exogenous genes, introduced therein, coding for the enzymes involved in the polymer synthesis. The enzymes involved in the aforementioned production are: i) the enzyme L-lactate dehydrogenase (EC 1.1.1.27), ii) the enzyme propionyl-CoA transferase (EC 2.8.3.1), iii) the enzyme polyhydroxyalkanoate synthase (EC 2.3.1.B3). Any L-lactate dehydrogenase enzyme, proprionyl-CoA transferase enzyme and polyhydroxyalkanoate synthase enzyme, whether encoded by an endogenous or heterologous gene, can be used according to the method of the invention. In a preferred embodiment, the heterologous gene encoding the enzyme L-lactate dehydrogenase is a mutated version of the ldh1 gene of Lactobacillus plantarum (Gene Accession no.: X70926). Specifically, this sequence has the following nucleotide mutations: T1A, T48C, C160G, G255T, G905C (Branduardi et al., 2006) (SEQ ID NO: 4).
In another preferred embodiment, the enzyme propionyl-CoA transferase is the mutated version of the enzyme propionyl-CoA transferase (Pct) of Clostridium propionicum. This mutated version, called Pct540, has an amino acid substitution at position 193 in which the valine is replaced by an alanine (V193A) (Park et al., WO2009/022797; Yang et al., 2010). Preferably the “codon usage” of the heterologous gene encoding the Pct of Clostridium propionicum (Gene ID: AJ276553), mutated in the Pct540 version, is optimized for translation in yeast (SEQ ID NO: 2).
In a further preferred embodiment, the enzyme polyhydroxyalkanoate synthase is the mutated version of the enzyme polyhydroxyalkanoate synthase C1 (PhaC1) of Pseudomonas resinovorans. This mutated version, called PhaC1437Pre, has four amino acid substitutions, in which the glutamic acid at position 130 is replaced by aspartic acid (E130D), the serine at position 325 is replaced by threonine (S325T), the serine at position 477 is replaced by glycine (S477G), glutamine at position 481 is replaced by lysine (Q481K) (Yang et al., 2011). Preferably, the “codon usage” of the heterologous gene encoding the PhaC1 of Pseudomonas resinovorans (Gene Accession no.: AF129396), mutated in the PhaC1437Pre version, is optimized for translation in yeast (SEQ ID NO: 3).
Surprisingly, the propionyl-CoA transferase and polyhydroxyalkanoate synthase enzymatic activities involved in PLLA production are the same as those required for PDLA synthesis. Unexpectedly, the present invention discloses that the enzymes propionyl-CoA transferase (Pct) and polyhydroxyalkanoate synthase C1 (PhaC1) can efficiently accept substrates in their enantiomeric form L. In literature there are no evidences that the enzyme propionyl-CoA transferase (Pct) can accept “in vivo” a substrate in the enantiomeric form L. The only study reported in literature has been conducted “in vitro” by Schweiger and Buckel (1984) and it shows that, although enzyme catalysis can occur on both isoforms, the enzyme has a clear preference of substrate with respect to D-lactate compared to the corresponding L form.
Similarly, considering the polyhydroxyalkanoate synthase, in literature there are no examples of polymerization conducted by this enzyme on monomers in the enantiomeric form L, independently from the polyhydroxyalkanoate synthase considered (type I, II, III).
This is clearly documented in BRENDA, one of the main database for known enzymes (https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B2, https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B3, https://www.brenda-enzymes.org/enzyme.php?ecno=2.3.1.B4). Consistently, the published productions of homo- and co-polymer of lactate in cells refer in fact to the polymerization of lactate monomers exclusively in the D form (Dusseaux et al., WO2017/108577; Lee et al., U.S. Pat. No. 9,120,891; and Cho et al., WO2006/126796).
Therefore, it is surprising that the cell(s) of the present invention is capable of producing a polyester biopolymer consisting of lactate monomers in the enantiomeric form L. This is further surprising if we consider that no polyester biopolymer synthesized by a cell (natural or engineered for the purpose) is constituted by monomers in enantiomeric form L: a clear example are the other polymers sharing bioplastic properties like the polyhydroxyalkanoates (PHA), which possess monomeric units exclusively in the D form (Singh and Yakhmi, 2017).
Since lactic acid is a key intermediate for the production of PDLA and/or PLLA, the intracellular production of this acid from glucose and/or other sugars, by engineering the expression levels of known genes, leads to an increase in production of lactic acid and therefore of PDLA and/or PLLA. Known engineered pathways for the efficient use of glucose and/or pentose sugars (xylose, arabinose) can be exploited for the production of PDLA and/or PLLA from sugars, which derive from residual biomass and therefore they are not in competition with the agri-food chain.
Therefore, according to a further embodiment, the cell able to produce PLLA/PDLA comprises intracellular levels of sugars and/or catabolic intermediates, deriving from them, greater than a corresponding wild-type cell, by cloning at least one of genes coding for proteins responsible for the internalization and/or catabolism of sugars. According to a preferred embodiment, said sugars are selected from glucose and carbohydrates deriving from chemical and/or enzymatic hydrolysis (enzymes belonging to the superfamilies of laccases, hydrolases, cellulases and hemicellulases, see Kumar et al., 2009) of a residual biomass. Preferably, said carbohydrates are hexoses and pentoses, including glucose, mannose, galactose, xylose, arabinose, and mixtures thereof. Therefore, the polymers of interest can be produced in a process that includes the hydrolysis of residual biomasses by enzymatic and/or chemical-physical means, for example by means of steam explosion, which leads to a solution enriched in simple sugars.
In addition or alternatively, intracellular lactic acid levels can be increased by eliminating competitive pathways to its production. As an illustrative and non-limiting example, the genes coding for pyruvate decarboxylase enzymes can be deleted (i.e. PDC1 Gene ID: 850733, Sequence NC_001144.5; PDC5 Gene ID ID: 850825, Sequence NC_001144.5; PDC6 Gene ID: 852978, Sequence NC_001139.9) and/or alcohol dehydrogenases, which lead to the formation of ethanol (i.e. ADHJ Gene ID: 854068, Sequence NC_001147.6).
Thus, in a further aspect the invention provides a process for the production of PLLA or PDLA that includes the following steps:
The cell used for the production of PLLA can be prokaryotic or eukaryotic. The cell used for the production of PDLA is eukaryotic. In a preferred embodiment, the eukaryotic cell is a yeast cell, more preferably a Saccharomyces cell and even more preferably a Saccharomyces cerevisiae cell. In a further preferred embodiment of the process for producing PDLA and/or PLLA according to the invention, aforementioned carbon source can be chosen among glucose and other sugars deriving from the hydrolysis of a residual biomass (i.e. hexose, pentose). Preferably, said sugars are hexose, preferably glucose, or pentose, preferably xylose and/or arabinose, and mixtures thereof.
In a further preferred embodiment of the PDLA and/or PLLA production process according to the invention, said carbon source can be present in an amount from 10 g/L to 1000 g/L, preferably being 20 g/L and 100 g/L.
In another preferred embodiment, the culture medium is not supplemented with lactic acid.
PDLA and/or PLLA extraction from cells can be performed using solvents.
Alternatively, the cellular biomass containing the polymer can be used directly.
The term “biomass” defines any substance of organic origin that can regenerate in times compatible with its consumption, destined for the production of bioenergy and/or biofuels and/or biomaterials. This contrasts with fossil biomasses, whose regeneration times exceed their consumption by several orders of magnitude.
“Residual biomass” means the biodegradable fraction of waste and/or residues of biological origin from agriculture (including vegetable and/or animal compounds) and/or from forestry and/or related industries, including fishing and/or aquaculture, mowing and pruning from public and private green areas, as well as the biodegradable part of industrial and/or urban waste.
The “production yield” is defined as the ratio between the quantity of product obtained and the quantity of substrate consumed.
The term “vector” indicates a DNA construct comprising a DNA sequence that is linked to a control sequence capable of leading to the expression of the aforementioned DNA in a suitable host. In this invention the typical plasmid vector used has: a) or an origin of replication which allows the effective replication of the plasmid so that in each cell of the selected host there are tens of copies of the plasmid vector, or a DNA sequence which allows the integration of the plasmid vector in a chromosome of each cell of the chosen host; b) a selection marker such that a cell correctly transformed with the plasmid vector can be selected; c) a DNA sequence comprising recognition sites for restriction enzymes in order to introduce exogenous DNA into the plasmid vector by a process called ligation.
As generally reported in the state of the art, in order to express the gene inserted in the host cell, the coding sequence must be correctly and functionally related to regulatory elements of transcription, translation and expression functioning in the selected expression host.
The term “transformation” here used means that the DNA, once introduced into the cell, can replicate outside of chromosomes or as part of an entire chromosome.
The coding sequence of the ldhA gene was amplified by PCR using as a template the genomic DNA of E. coli and specific oligonucleotides (SEQ ID NO: 5; SEQ ID NO: 6). It is as follows: after 30 seconds of denaturation at 98° C., 25 cycles (denaturation of 10 seconds at 98° C., annealing of 30 seconds at 72° C. and elongation of 60 seconds at 72° C.), followed by a final elongation of 2 minutes at 72° C. The PCR product and the pTEFLEU2 target vector were digested with the EcoRI and XhoI restriction enzymes and after their ligation, the recombinant pTEFLEU2-ldhA vector was obtained (
The ldh1 gene of L. plantarum (SEQ ID NO: 4) was excised from the vector p022TLP (Branduardi et al., 2006) by digestion with the EcoRI restriction enzyme. The DNA fragment corresponding to the ldh1 gene having EcoRI ends was ligated with the target vector pTEFLEU2, after its digestion with EcoRI, leading to the obtainment of the recombinant expression vector pTEFLEU2-ldh1 (
The coding sequence of the mutated version of the Pct gene of C. propionicum, Pct540 (SEQ ID NO: 3), preceded by the sequence of the pTDH3 promoter of S. cerevisiae (SEQ ID NO: 7) have been synthesized de novo and cloned by the manufacturing company into the pEX-A2 vector (Eurofins Genomics), obtaining the pEX-A2-Pct540 vector. In particular, the sequence of the Pct540 gene has codon usage optimized for yeast cells. The pEX-A2-Pct540 vector was linearized with the restriction enzyme BglI, and the pTDH3-Pct540 DNA fragment was excised from the aforementioned linearized vector, by digestion with the restriction enzymes KpnI and NheI. The pTDH3-Pct540 fragment with KpnI/NheI ends was cloned in the target vector pYX212 (R&D Systems, Inc., Wiesbaden, D), digested with the restriction enzymes KpnI and NheI and therefore lacking the pTPI promoter of S. cerevisiae. The ligation of the two DNA fragments led to the obtainment of the recombinant expression vector pYX212-Pct540 (
The coding sequence of the mutated version of the PhaC1 gene of P. resinovorans, or PhaC1437Pre (SEQ ID NO: 3), preceded by the sequence of the pADH1 promoter of S. cerevisiae (SEQ ID NO: 8) have been synthesized de novo and cloned by the manufacturing company into the pEX-K4 vector (Eurofins Genomics). In particular, the PhaC1437Pre gene sequence has codon usage optimized for yeast cells. The pADH1-PhaC1437Pre DNA fragment was excised by the pEX-K4 vector by digestion with the restriction enzymes AatII and NheI. The pADH1-PhaC1437Pre fragment with AatII/NheI ends was cloned in the target vector pYX022 (R&D Systems, Inc., Wiesbaden, D), digested with the restriction enzymes AatII and NheI and therefore lacking the pTPI promoter of S. cerevisiae. The ligation of the two DNA fragments led to the obtainment of the recombinant expression vector pYX022-PhaC1437Pre (
The CEN.PK laboratory strain of S. cerevisiae was transformed with the vectors pTEFLEU2-ldhA, pYX212-Pct540 and pYX022-PhaC1437Pre, described respectively in examples 1, 3, 4. The graphic representation of the metabolic pathway for PDLA synthesis starting from glucose via pyruvate, D-lactate and D-lactoyl-CoA, in the recombinant strain is shown in
The S. cerevisiae CEN.PK laboratory strain was transformed with the vectors pTEFLEU2-ldh1, pYX212-Pct540 and pYX022-PhaC1437Pre, described respectively in examples 2, 3, 4. The graphic representation of the metabolic pathway for PLLA synthesis starting from glucose via pyruvate, L-lactate and L-lactyl-CoA, in the recombinant strain is shown in
The S. cerevisiae CEN.PK laboratory strain was transformed with the pTEFLEU2-ldhA and pYX212-Pct540 vectors. The aforementioned recombinant strain lacks the polyhydroxyalkanoate synthase activity and it is therefore used in the following examples as a negative control for PDLA and PLLA production. In fact, independently of the stereochemistry of lactate, the absence of polyhydroxyalkanoate synthase activity does not allow the polymerization of lactyl-CoA monomers.
Cells of the CEN.PK pTEFLEU2-ldhA, pYX212-Pct540, pYX022-PhaC1437Pre strain engineered for the production of PDLA, of the CEN.PK pTEFLEU2-ldh1, pYX212-Pct540, pYX022-PhaC1437Pre strain engineered for the production of PLLA and CEN.PK pTEFLEU2-ldhA, pYX212-Pct540 strain (used as a control) were grown in the presence of glucose 20 g/L and Yeast Nitrogen Base (YNB) 6.7 g/L. The cells were inoculated at an optical density of 0.05 (OD 660 nm) in 20 mL of medium in 100 mL flasks and incubated at 30° C. on an orbital shaker at 160 rpm. Cell growth was monitored by measuring OD at 660 nm at regular time intervals. The extracellular concentration of glucose, acetate, ethanol and glycerol was determined by HPLC using H2SO4 5 mN as a mobile phase and a Rezex ROA H+ column (8%) 300×7.8 mm with styrene sulfonate-divinylbenzene matrix (Phenomenex).
As shown in
A carbon flux redirection in cells transformed with the genes encoding the enzymatic activities necessary for the production of PDLA and PLLA is demonstrated by these experiments.
The cells of the CEN.PK strain engineered for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the ldha and Pct540 genes were grown as described in Example 8. The production of PDLA or alternatively of PLLA was evaluated by staining with Nile red dye. Nile red is generally used to evaluate in live cells the accumulation of aliphatic biopolymers, such as PHA or co-polymers of D-lactic acid and other hydroxy acids, as reported in literature, by way of example, by Spiekermann et al., 1999; Glorenflo et al., 1999; Yang et al., 2010. Specifically, after 24, 48 and 72 hours from the inoculum, 0.3 OD of cells of the strains were collected and after centrifugation washed with 1 mL of phosphate buffer (PBS; NaH2PO4 53 mM, Na2HPO4 613 mM, 75 mM NaCl). After centrifugation, they were resuspended in 1 mL of 35% (v/v) cold ethanol and incubated in ice for 20 minutes in order to permeabilize the cells to Nile red. The cells were washed again with 1 mL of PBS, and, after the addition of Nile red at the final concentration of 31.4 μM, they were incubated for 5 minutes in the dark in ice. Subsequently, the samples were analyzed by flow cytometry (FACS), using a Beckman Coulter FC-500 flow cytometer (Beckman Coulter, Fullerton, Calif., USA) equipped with an argon ion laser (excitation wavelength 488 nm, laser power 20 mW). The fluorescence emission of Nile red is acquired through a 670 nm filter (FL3 channel), in a logarithmic scale. The operating parameters were set to analyze 20 thousand cells for each sample excluding cellular debris. The data were subsequently analyzed using the Flowing software program (www.flowingsoftware.com).
The dot plots show that almost all the cells engineered for the production of PDLA (panel B) and for the production of PLLA (panel C) are positive to Nile red staining. In particular, the maximum percentage of cells positive to the staining is 84% in the engineered strain for PDLA production and 97% in the PLLA-engineered strain. On the contrary, as can be observed in panel A, in the control cells expressing only the ldhA and Pct540 genes, the percentage of staining positive cells is negligible and attributable to the interaction of Nile red with structural components of the cell, such as cell membranes (Mukherjee et al., 2007).
Given the direct correlation between the fluorescence emission of Nile red and the presence of aliphatic polymers, the reported data demonstrate that the metabolic engineering aimed at producing PDLA and/or PLLA (
Therefore, the synthesis of PDLA in eukaryotic cells by means of a one-step production, without the addition of lactate as substrate, without any mandatory need to attenuate or eliminate the ability to consume lactic acid as carbon source and without any mandatory need to increase the productivity of intracellular Coenzyme A (CoA) donor is described here for the first time. Furthermore, the direct synthesis of PLLA by cells is described for the first time. In literature no examples report wild-type or engineered cells capable of polymerizing hydroxy acids, and lactic acid among them, with a chiral center in L configuration. In particular, it has been described here for the first time that the enzyme polyhydroxyalkanoate synthase is able to polymerize hydroxy acid monomers with L configuration of the chiral center.
In addition, the cells of the CEN.PK strain engineered for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the ldha and Pct540 genes were grown on agar plates with molasses 20 g/L as carbon source, supplement with Nile red dye 0.5 μg/mL. After 4 days of incubation at 30° C., cell growth was observed in all the strains but only the strain engineered for PDLA production and that one engineered for PLLA production were able to accumulate intracellularly PDLA or PLLA, respectively, they indeed resulted stained with Nile red when exposed to UV light.
In order to evaluate the composition of the polymer accumulated in the cells (example 9) a gas chromatography mass spectrometry (GC-MS) analysis was performed.
The cells of the engineered strain for PDLA production, of the engineered strain for PLLA production and of the control strain expressing only the ldha and Pct540 genes were pre-inoculated in the presence of glucose 50 g/L and YNB 6.7 g/L. The preinoculum was performed in 100 mL of medium in 500 mL flasks incubated at 30° C. on an orbital shaker at 160 rpm. After 24 hours of growth, cells were inoculated into a 2 L bioreactor at an initial OD660 of 0.2. The operating volume of the media used in the bioreactor is 1.5 L and its composition is: glucose 50 g/L and YNB 13.4 g/L.
Growth parameters are: constant temperature of 30° C.; amount of dissolved oxygen greater than 25% with an air flow of 1 vvm (volume of air per volume of culture medium); pH maintained at 5 with additions, if necessary, of NaOH 4M and H3PO4 at 25% (v/v). Agitation is dependent on the percentage of oxygen dissolved in the media.
After 48 hours from the inoculum, cells were collected by centrifugation and subjected to lyophilization and then to acid methanolysis in order to break the cells and depolymerize the lactic acid polymer into methyl lactate monomer units. Methanolysis was performed according to the following protocol adapted by Braunegg et al. (1978): the cells were dissolved in a solution of methanol acidified with sulfuric acid (3% v/v) and chloroform in a 1:1 ratio; the mixture was heated in microwave at a power of 300 W, for 200 minutes at 120° C. The solution resulting from the methanolysis of the cells was analyzed by GC-MS.
This instrument consists of a Clarus 500 gas chromatograph (PerkinElmer) and a Clarus 560 mass spectrometer (PerkinElmer). The GC is equipped with an Elite-5MS capillary column (PerkinElmer). The temperature conditions in which the gas chromatographic analysis was carried out are the following: 70° C. for 5 minutes, increase of 10° C./minute up to 150° C., increase of 20° C./minute to reach 300° C., maintained for 14.5 minutes. The sample was injected at an initial temperature of 250° C., maintained for 10 minutes.
| Number | Date | Country | Kind |
|---|---|---|---|
| 102018000007846 | Aug 2018 | IT | national |
This application is the U.S. national phase of International Application No. PCT/EP2019/070665 filed Jul. 31, 2019 which designated the U.S. and claims priority to IT 102018000007846 filed Aug. 3, 2018, the entire contents of each of which are hereby incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/070665 | 7/31/2019 | WO | 00 |
